1.
High risk of overdose death following release from prison: variations in mortality during a 15-year observation period.
by Bukten, Anne
Addiction (Abingdon, England), August 2017, Vol.112(8), pp.1432-1439

2.
Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study
by Mcdonald, Rebecca
Addiction, March 2018, Vol.113(3), pp.484-493

3.
Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post‐dosing: analysis of suitability for opioid overdose reversal
by Mundin, Gill
Addiction, September 2017, Vol.112(9), pp.1647-1652

4.
Qualitative evaluation of a novel contingency management-related intervention for patients receiving supervised injectable opioid treatment
by Neale, Joanne
Addiction, April 2016, Vol.111(4), pp.665-674

5.
The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom
by Hickman, Matthew
Addiction, August 2018, Vol.113(8), pp.1461-1476

6.
Randomized controlled pilot trial of naloxone-on-release to prevent post-prison opioid overdose deaths
by Parmar, Mahesh
Addiction, March 2017, Vol.112(3), pp.502-515

7.
Training family members to manage heroin overdose and administer naloxone: randomized trial of effects on knowledge and attitudes
by Williams, Anna
Addiction, Feb 2014, Vol.109(2), pp.250-259

8.
Improving recruitment to pharmacological trials for illicit opioid use: findings from a qualitative focus group study
by Neale, Joanne
Addiction, Jun 2018, Vol.113(6), pp.1066-1076

9.
Excess overdose mortality immediately following transfer of patients and their care as well as after cessation of opioid substitution therapy
by Bogdanowicz, Karolina
Addiction, May 2018, Vol.113(5), pp.946-951

10.
Evaluation of a transdermal buprenorphine formulation in opioid detoxification
by Lanier, Ryan
Addiction, 0, 2007, Vol.102(10), pp.1648-1656

11.
Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995-2005
by Sheridan, Janie
Addiction, Nov 2007, Vol.102(11), pp.1824-1830

12.

13.
Should we worry that take‐home naloxone availability may increase opioid use?
by Humphreys, Keith
Addiction, Oct 2019, pp.1723-1725

14.
Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder
by Frost, Michael
Addiction, Aug 2019, Vol.114(8), pp.1416-1426
